<ѻýҕl>Multi-Cancer Early Detection: 20th-Century Fiction Becomes Realityѻýҕl> These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
<ѻýҕl>Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLCѻýҕl> Approach is "potentially practice-changing," editorialist says Jul 20, 2023
<ѻýҕl>Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Useѻýҕl> But PFS, OS longer with ICIs plus chemotherapy among patients treated with PPIs Jul 11, 2023
<ѻýҕl>Hooray! A Clearer Estimate of Your Risk for Death Is Hereѻýҕl> Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
<ѻýҕl>TTFields Therapy Yields OS Improvement in Second-Line NSCLCѻýҕl> However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
<ѻýҕl>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLCѻýҕl> "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
<ѻýҕl>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Yearsѻýҕl> Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
<ѻýҕl>New Data in NSCLC Bolster Support for Perioperative Immunotherapyѻýҕl> EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
<ѻýҕl>New Standard in Operable EGFR-Positive Lung Cancerѻýҕl> "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
<ѻýҕl>Lung Cancer Screening Results Influence Follow-Up Adherenceѻýҕl> Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
<ѻýҕl>'Potential' New Option for Operable NSCLCѻýҕl> Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
<ѻýҕl>FDA Allows Lower Risk Designation for Snuff Productѻýҕl> The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
<ѻýҕl>AI Tool Forecasts Lung Cancer Risk From a Single CT Scanѻýҕl> Experts give high marks to performance of "Sybil" in predicting disease over 6 years Feb 07, 2023
<ѻýҕl>Risk Model-Based Lung Cancer Screening More Cost-Effective Than USPSTF Recsѻýҕl> Risk prediction models more sensitive than age-, smoking history-based methods Feb 07, 2023
<ѻýҕl>Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancerѻýҕl> A majority of patients obtained disease control with tarlatamab; responses proved durable Feb 01, 2023
<ѻýҕl>Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patientsѻýҕl> Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
<ѻýҕl>Xeljanz Cancer Risks Detailedѻýҕl> New paper provides full results from ORAL Surveillance trial Dec 07, 2022
<ѻýҕl>Lung Cancer Survival High for Patients With Early, Screen-Detected Tumorsѻýҕl> Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate Nov 28, 2022
<ѻýҕl>Lung Cancer Screening Programs Hit the Mark on Eligibility Criteriaѻýҕl> However, adherence to follow-up screening is "suboptimal" Oct 10, 2022
<ѻýҕl>FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancersѻýҕl> Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
<ѻýҕl>KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLCѻýҕl> "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
<ѻýҕl>Survival Bump in Unfit NSCLC With First-Line Immunotherapyѻýҕl> Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
<ѻýҕl>Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinibѻýҕl> About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
<ѻýҕl>Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLCѻýҕl> Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
<ѻýҕl>Study: Microwave Ablation for Lung Nodules Effective as Last Resortѻýҕl> Good option for patients who can't have surgery or radiotherapy, surgeon says Sep 08, 2022
<ѻýҕl>'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Comboѻýҕl> Long-term follow-up shows continued survival benefit as first-line treatment Aug 11, 2022
<ѻýҕl>Triple Therapy Continues to Impress in Metastatic NSCLC With High-Risk Mutationsѻýҕl> Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo Aug 10, 2022
<ѻýҕl>Survey: 77% of Women With Lung Cancer Report Sexual Dysfunctionѻýҕl> Results show need to integrate sexual health into care, researcher says Aug 09, 2022
<ѻýҕl>Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLCѻýҕl> Phase II trial supports neoadjuvant nivolumab plus chemotherapy Aug 09, 2022
<ѻýҕl>New Data Bolster Atezolizumab as Adjuvant Tx in NSCLCѻýҕl> Overall survival benefit now demonstrated Aug 09, 2022
<ѻýҕl>Low-Dose Sotorasib 'Lead-in' Strategy Promising in NSCLC Subsetѻýҕl> Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option Aug 08, 2022
<ѻýҕl>Sublobar Resection the 'New Standard of Care' in Small-Sized NSCLC?ѻýҕl> Large randomized study shows non-inferiority to lobectomy Aug 08, 2022
<ѻýҕl>Lorlatinib Reduces CNS Progression in ALK-Positive NSCLCѻýҕl> Post-hoc analysis of CROWN trial does find more central nervous system toxicity, however Jun 14, 2022
<ѻýҕl>Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancerѻýҕl> No change in survival when combined with atezolizumab and chemotherapy Jun 06, 2022
<ѻýҕl>Durvalumab Combinations Push the Response Envelope in Unresectable NSCLCѻýҕl> Big increases in response, disease control with the addition of anti-CD73, anti-NKG2A agents May 02, 2022
<ѻýҕl>Boosting Responses to Neoadjuvant Therapy in Resectable NSCLCѻýҕl> Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
<ѻýҕl>Neoadjuvant Nivolumab a 'New Standard' in Lung Cancerѻýҕl> "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
<ѻýҕl>Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLCѻýҕl> Prolonged tumor response seen in 2-year analysis Apr 11, 2022
<ѻýҕl>More Research Needed on Use of Premium Cigars, Report Findsѻýҕl> These cigars seem less dangerous than cigarettes -- but it's only because of how they are smoked Mar 10, 2022
<ѻýҕl>Cancer May Heighten Odds of Guillain-Barre Syndromeѻýҕl> Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022